Finance in Practice, the VC perspective

Wednesday, 26 June 2024, 11:00 - 12:00


Charlotte Kremers, PhD. | Investment Analyst, M Ventures

Charlotte Kremers, PhD, is an Analyst in the Biotechnology team, having joined M Ventures as a Fellow in September 2022. Charlotte received her BSc in Cell Biology, Physiology and Neuroscience from University College Utrecht and MSc in Neuroscience from University College London. She completed her PhD in Neuroscience at UCL in 2022, during which she investigated the pathomechanisms underlying a juvenile form of Amyotrophic Lateral Sclerosis. Throughout her academic career, Charlotte was active in extracurricular activities, among others acting as a student biotech consultant, leading a sponsorship committee and organizing two conferences. She is based in Amsterdam at the M Ventures head office.


M Ventures

M Ventures is the strategic, corporate venture capital arm of Merck. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck’s current and future businesses.

Finance in Practice - The VC Perspective

Young companies that aim to develop technology-based products or services, in many cases require significant capital and time to reach the market. This is true in particular for companies active in drug and medical technology development, which are even more cash hungry, and may take up to a decade before they have regulatory clearance and can start selling their product to establish some earnings. Subsidies may provide the initial funding, while banks will only be prepared to step in once products are actually being sold and a positive cash flow is in sight. Enter venture capital, to fund the “valley of death” that lies in between the initial soft monies and the banks. This talk will address how venture capitalists work in this specific field. What do we look for, what are the latest biotech investment trends, what does the due diligence process entail, how do we interact with our (future) portfolio companies and how do we make our returns?

Powered by:
BCF Courses BV   

    Connect with us                  

Join BioBusiness Summer School
Privacy Policy
Terms & Conditions 
Chamber of Commerce: 75874415
         
  
  
  
                                     
        REGISTER NOW
    

© Copyright 2020 by BCF Courses